Banque Pictet & Cie’s Sarepta Therapeutics SRPT Stock Holding History

Banque Pictet & Cie’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,236	Closed	-$207K	–	403
2025 Q1	$207K	Sell	3,236 -40,750	-93%	-$4.29M	﹤0.01%	381
2024 Q4	$5.35M	Sell	43,986 -4,059	-8%	-$497K	0.04%	148
2024 Q3	$6M	Buy	48,045 +13,521	+39%	+$1.87M	0.05%	137
2024 Q2	$5.45M	Buy	+34,524	New	+$4.44M	0.05%	142
2023 Q3	–	Sell	-26,760	Closed	-$3.06M	–	508
2023 Q2	$3.06M	Buy	26,760 +22,028	+466%	+$2.84M	0.03%	201
2023 Q1	$652K	Sell	4,732 -2,146	-31%	-$278K	0.01%	429
2022 Q4	$891K	Sell	6,878 -36,372	-84%	-$4.21M	0.01%	414
2022 Q3	$4.78M	Buy	43,250 +26,570	+159%	+$2.68M	0.05%	182
2022 Q2	$1.25K	Buy	16,680 +2,062	+14%	+$152K	0.01%	392
2022 Q1	$1.14M	Buy	+14,618	New	+$1.12M	0.01%	424

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Banque Pictet & Cie's SRPT Position: Q2 2025 in Review

Banque Pictet & Cie sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 3,236 shares — an estimated $207K sold.

Banque Pictet & Cie first reported a position in SRPT in Q1 2022 and held it in 10 quarters. The position peaked at $6M in Q3 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

Banque Pictet & Cie reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
Banque Pictet & Cie sold 3,236 Sarepta Therapeutics shares in Q2 2025, an estimated $207K.
Banque Pictet & Cie first reported a position in Sarepta Therapeutics in Q1 2022 and held it in 10 quarters.
Banque Pictet & Cie's Sarepta Therapeutics position peaked at $6M in Q3 2024.
362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Banque Pictet & Cie's 13F filing for Q2 2025, filed 16 Jul 2025.